Biological function integrated prediction of severe radiographic progression in rheumatoid arthritis: a nested case control study

Abstract

BackgroundRadiographic progression is reported to be highly heritable in rheumatoid arthritis (RA). However, previous study using genetic loci showed an insufficient accuracy of prediction for radiographic progression. The aim of this study is to identify a biologically relevant prediction model of radiographic progression in patients with RA using a genome-wide association study (GWAS) combined with bioinformatics analysis.MethodsWe obtained genome-wide single nucleotide polymorphism (SNP) data for 374 Korean patients with RA using Illumina HumanOmni2.5Exome-8 arrays. Radiographic progression was measured using the yearly Sharp/van der Heijde modified score rate, and categorized in no or severe progression. Significant SNPs for severe radiographic progression from GWAS were mapped on the functional genes and reprioritized by post-GWAS analysis. For robust prediction of radiographic progression, tenfold cross-validation using a support vector machine (SVM) classifier was conducted. Accuracy was used for selection of optimal SNPs set in the Hanyang Bae RA cohort. The performance of our final model was compared with that of other models based on GWAS results and SPOT (one of the post-GWAS analyses) using receiver operating characteristic (ROC) curves. The reliability of our model was confirmed using GWAS data of Caucasian patients with RA.ResultsA total of 36,091 significant SNPs with a p value <0.05 from GWAS were reprioritized using post-GWAS analysis and approximately 2700 were identified as SNPs related to RA biological features. The best average accuracy of ten groups was 0.6015 with 85 SNPs, and this increased to 0.7481 when combined with clinical information. In comparisons of the performance of the model, the 0.7872 area under the curve (AUC) in our model was superior to that obtained with GWAS (AUC 0.6586, p value 8.97 × 10-5) or SPOT (AUC 0.7449, p value 0.0423). Our model strategy also showed superior prediction accuracy in Caucasian patients with RA compared with GWAS (p value 0.0049) and SPOT (p value 0.0151).ConclusionsUsing various biological functions of SNPs and repeated machine learning, our model could predict severe radiographic progression relevantly and robustly in patients with RA compared with models using only GWAS results or other post-GWAS tools.Electronic supplementary materialThe online version of this article (doi:10.1186/s13075-017-1414-x) contains supplementary material, which is available to authorized users.

A systematic review of the applications of artificial intelligence and machine learning in autoimmune diseases

“…The majority of data used was clinical, with very few papers utilising 'omic data. 86,[97][98][99] Monitoring and management Ten different studies of type 1 diabetes (T1D) used ML for monitoring and management: four predicted blood glucose level, four identified or predicted hypoglycaemic events, and two supported decision making using case-based reasoning or decision support systems. The majority of models used clinical data.…”

Molecular and Cellular Heterogeneity in Rheumatoid Arthritis: Mechanisms and Clinical Implications

“…Among them, the rs2833522 region contains H3K4me3 histone markers, transcription factors, and long non-coding RNAs, which are related to the degree of bone destruction in ACPA-negative RA patients (34). A modern and more accurate method of predicting the impact of SNPs on RArelated radiological characteristics involves the combination of genome-wide association study (GWAS) with bioinformatic analysis and repeated machine learning (39).…”

Genetic-Driven Druggable Target Identification and Validation

“…Unfortunately, collecting measures of progression and severity in case-only studies is inherently more difficult than acquiring yes–no answers about disease status in case–control studies. Indeed, only a small proportion of GWAS, typically with smaller sample sizes and, hence, reduced statistical power compared with standard GWAS, were conducted to identify variants associated with disease progression, which could be more informative to identify ameliorating therapies [88,89]. Such case-only GWAS may become more extensive as longitudinal and retrospective clinical data are accumulated for large disease cohorts and will further extend the impact of genetics on the development of new drugs.…”